Cardiology Month in Review: December 2021

Each month, our editorial staff compiles a month in review highlighting the most popular content from the past month. December's month in review features new guidelines, FDA news, and more.

Editor's note: Clicking on a slide will redirect you to that article.

Top Stories from December 2021

  1. FDA Approves Twice-Yearly Inclisiran (Leqvio) for Lowering Cholesterol in ASCVD, HeFH

    Announced on December 22, the approval of inclisiran (Leqvio) comes nearly a year after the original PDUFA date. With approval, inclisiran becomes the first and only siRNA therapy approved to lower LDL-C with twice-yearly dosing.
  2. AHA Releases New Statement on Diagnosing, Managing Hypertensive Disorders of Pregnancy

    Released on Dec. 15, the latest scientific statement from the American Heart Association provides a comprehensive overview of the available evidence on topics related to diagnosis, management, and pharmacotherapy for hypertension during pregnancy.
  3. Noteworthy Cardiology Posters from the World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease

    The Practical Cardiology editorial staff has compiled a list of 6 noteworthy posters related to cardiology from the Metabolic Institute of America's 19th annual World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease.
  4. New Revascularization Guidelines Released by ACC, AHA, and SCAI

    The ACC/AHA/SCAI 2021 guideline recommendations for coronary artery revascularization were released on December 9, which they hope will replace or retire recommendations from half a dozen previous guidelines.
  5. American Heart Association Report Raises Alarm on Blood Pressure Increases During Pandemic

    A report published in Circulation details per month increases in both systolic and diastolic blood pressure observed during the pandemic as compared with prepandemic periods.